Fereshteh Asgharzadeh1, Alireza Hashemzadeh1, Farzad Rahmani2, Atieh Yaghoubi3, Seyedeh Elnaz Nazari1, Amir Avan4, Seyed Mahdi Hasanian Mehr5, Saman Soleimanpour6, Majid Khazaei7. 1. Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Department of Biochemistry, Faculty of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran. 3. Antimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 5. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Biochemistry, Mashhad University of Medical Sciences, Mashhad, Iran; Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 6. Antimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: soleimanpours@mums.ac.ir. 7. Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: Khazaeim@mums.ac.ir.
Abstract
BACKGROUND: Cerium (IV) oxide (CeO2) exhibit anti-inflammatory activity via scavenge free radicals and decreasing the oxygen species (ROS) production. Here we aimed to exhibit the therapeutic effect of this nanoparticle in experimental colitis models. METHODS: Cerium oxide nanoparticles (CeONPs) were synthesized via using UiO-66 as a precursor. We used dextran sodium sulfate (DSS) to induce colitis in experimental models to investigate the anti-inflammatory effect of CeONPs. Colitis models are divided into four groups to receive the treatment, including control, colitis, cerium oxide, and sulfasalazine. We evaluated the therapeutic effects of CeONPs for the increased colitis clinical symptoms and attenuated the histological damage to colon tissue in colitis. RESULT: This nanoparticle was significantly able to reduce the clinical symptoms of colitis. Moreover, CeONPs can enhance the disease activity index such as body lose weight, diarrhea, rectal bleeding, colon length, and spleen weight. Moreover, CeONPs showed a significant reduction in the histological characteristics of the colitis models. CONCLUSION: These results suggest that CeONPs can be considered as promising therapeutic agents in treating the ulcerative colitis.
BACKGROUND:Cerium (IV) oxide (CeO2) exhibit anti-inflammatory activity via scavenge free radicals and decreasing the oxygen species (ROS) production. Here we aimed to exhibit the therapeutic effect of this nanoparticle in experimental colitis models. METHODS:Cerium oxide nanoparticles (CeONPs) were synthesized via using UiO-66 as a precursor. We used dextran sodium sulfate (DSS) to induce colitis in experimental models to investigate the anti-inflammatory effect of CeONPs. Colitis models are divided into four groups to receive the treatment, including control, colitis, cerium oxide, and sulfasalazine. We evaluated the therapeutic effects of CeONPs for the increased colitis clinical symptoms and attenuated the histological damage to colon tissue in colitis. RESULT: This nanoparticle was significantly able to reduce the clinical symptoms of colitis. Moreover, CeONPs can enhance the disease activity index such as body lose weight, diarrhea, rectal bleeding, colon length, and spleen weight. Moreover, CeONPs showed a significant reduction in the histological characteristics of the colitis models. CONCLUSION: These results suggest that CeONPs can be considered as promising therapeutic agents in treating the ulcerative colitis.
Authors: Jatin Machhi; Pravin Yeapuri; Milica Markovic; Milankumar Patel; Wenhui Yan; Yaman Lu; Jacob D Cohen; Mahmudul Hasan; Mai Mohamed Abdelmoaty; You Zhou; Huangui Xiong; Xinglong Wang; R Lee Mosley; Howard E Gendelman; Bhavesh D Kevadiya Journal: ACS Chem Neurosci Date: 2022-03-21 Impact factor: 5.780
Authors: Adriana Sofranko; Tina Wahle; Julia Kolling; Harm J Heusinkveld; Burkhard Stahlmecke; Martin Rosenbruch; Catrin Albrecht; Roel P F Schins Journal: Part Fibre Toxicol Date: 2022-03-25 Impact factor: 9.400